Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24567587 | 0.87 | PKM (0.67) | PKMKMT2AHSD17B10RECQLPOLB | |
| SCHEMBL12407115 | 0.85 | PKM (0.52) | PKMKMT2AHSD17B10RECQLPOLB | |
| SCHEMBL27193044 | 0.84 | RAB9A (0.77) | PKMRECQLPOLBRAB9ANPC1 | |
| SCHEMBL27266163 | 0.83 | NPC1 (0.64) | PKMKMT2AHSD17B10RECQLPOLB | |
| SCHEMBL12780368 | 0.83 | RECQL (0.61) | PKMKMT2AHSD17B10RECQLPOLB | |
| SCHEMBL21141305 | 0.82 | PKM (0.64) | PKMKMT2AHSD17B10RECQLPOLB | |
| SCHEMBL11426554 | 0.81 | RAB9A (0.63) | PKMKMT2AHSD17B10RECQLPOLB | |
| SCHEMBL23136501 | 0.81 | RECQL (0.68) | PKMKMT2AHSD17B10RECQLPOLB | |
| SCHEMBL17049551 | 0.79 | SMN1; SMN2 (0.73) | KMT2APOLBRAB9ANPC1HTT | |
| SCHEMBL2711059 | 0.79 | RECQL (0.57) | PKMKMT2AHSD17B10RECQLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-14 | — | — | US | disclosed |
| US-9120810-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BOARD INSTITUTE, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| CN-1021819-C | PROCESS FOR DIUREA DERIVATIVES USEFUL AS MEDICAMENTS | YAMANOUCHI PHARMA CO LTD (JP) | 1993-08-18 | — | — | CN | disclosed |
| CN-1034538-A | As useful diurea derivatives of medicine and preparation method thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1989-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | PKM 2578/4885KMT2A 506/4885HSD17B10 753/4885 |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | IDH1, IDH2, IDH3A | PKM 924/4885KMT2A 1147/4885HSD17B10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.